Showing 321 - 340 results of 550 for search '"pharmacy"', query time: 0.06s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325

    Assessing the Economic Burden and Health Care Utilizations of U.S. Veteran Patients with Schizophrenia by Lin Xie, M. Furaha Kariburyo, Juan Du, Yuexi Wang

    Published 2013-10-01
    “…Patients in both groups were required to be at least age 18 years and have continuous medical and pharmacy benefits 1 year pre- and 1 year post-index date. …”
    Get full text
    Article
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330

    Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans by Rolin L. Wade, Chi-Chang Chen, Ajita P. De, Jaren C. Howard

    Published 2017-07-01
    “…**Background:** Previous research demonstrated that utilization management (UM) such as prior authorization (PA) or non-formulary (NF) restrictions may reduce pharmacy costs when designed and applied appropriately to certain drug classes. …”
    Get full text
    Article
  11. 331
  12. 332
  13. 333

    Economic Burden of HIV in a Commercially Insured Population in the United States by Cindy Y. Chen, Prina Donga, Alicia K. Campbell, Babafemi Taiwo

    Published 2023-01-01
    “…All-cause costs PPPM for adults with PrEP were $1761 ($1938), with pharmacy costs accounting for 71%. **Conclusions:** Despite advances in ART, patients with newly diagnosed HIV and at-risk patients receiving PrEP continue to incur HRU costs. …”
    Get full text
    Article
  14. 334
  15. 335
  16. 336
  17. 337
  18. 338

    Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn’s Disease Initiating Biologics With 3 Years of Follow-Up by Ruizhi Zhao, Zhijie Ding, Parul Gupta, Laurence Gozalo, Robert Bruette, Victor M. Johnson, Keshia Maughn, Yihang Liu, Sumesh Kachroo

    Published 2023-11-01
    “…**Methods:** This retrospective observational study was conducted using the STATinMED RWD Insights all-payer medical and pharmacy data. Adult patients with at least 1 CD medical claim and at least 1 medical/pharmacy claim for a biologic (adalimumab \[ADA\], certolizumab pegol (CZP), infliximab \[IFX\] and its biosimilar products \[IFX-BS\], ustekinumab \[UST\], and vedolizumab \[VDZ\]) between September 2016 and October 2018 were identified. …”
    Get full text
    Article
  19. 339
  20. 340